Overcoming obstacles in personalised medicine
Tune in to this episode to learn how overcoming the key challenges in personalised medicine could transform the future of healthcare.
List view / Grid view
Tune in to this episode to learn how overcoming the key challenges in personalised medicine could transform the future of healthcare.
To fully unlock the potential of immunotherapy for cancer patients, we need better targets, not just better treatments. Hear from Michelle Teng, CEO of Etcembly, on how AI is decoding the immune repertoire and designing new therapies.
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
A University of Sydney study reveals how DNA origami can build programmable nanostructures, with promising applications in targeted drug delivery and nanorobotics.
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
New collaboration focuses on transforming academic research into innovative therapies for urgent medical conditions, including cancer and heart disease.
Driven by a passion for innovation and inclusivity, Dr Catherine Pickering, CEO of iOnctura, is on a mission to transform cancer treatment while championing diversity within the biotech industry.
Researchers have uncovered a how INPP4B, alongside PIKfyve and TRPML-1, drives pancreatic cancer metastasis.
16 October 2024 | By
Ludwig Cancer Research researchers have designed and validated a computational pipeline which integrates molecular and genetic analyses.
A new study, presented at the United European Gastroenterology, reveals how chronic stress disturbs the balance of gut microbiota and influences CRC progression.
Cancer Research UK-funded researchers aim to identify targets for an ovarian cancer vaccine, which could prevent the disease at an early stage.
Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes.
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional…
The researchers discovered that anti-PD-1 autoantibodies influence the outcome of Atezo/Bev therapy for hepatocellular carcinoma.